News
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback